Prescription requirements and telehealth models — a second dataset posts 61–90

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

The evidence for this is thinner than the way I have phrased it suggests.

The failure mode on Prescription requirements and telehealth models is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

Building on post #60 rather than restating it.

Practical answer on Prescription requirements and telehealth models, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.

Post #62 put the caveat in the right place and I want to underline it.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

If anyone has run this properly I would rather read that than my own guess.

That is clearer than the version I had in my head. Thank you.

Scheduling and prescription status are separate questions and the answer to one does not imply the other.

One of those cases where knowing the mechanism does not help the decision.

Prescription requirements and telehealth models is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

Where I part company with post #66, and it is a narrow parting.

I would call the community position on Prescription requirements and telehealth models likely rather than established, and I would be comfortable defending that hedge.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

On post #66 — agreed on the reasoning, with one qualification.

Agreed on Prescription requirements and telehealth models, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

The short answer was in the first line; everything after is the working.

Picking up post #69: that is the part I would want checked first.

The useful distinction on Prescription requirements and telehealth models is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.

Source for the Prescription requirements and telehealth models figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.

Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.

I will take the caveat as seriously as the claim, which is the point of putting it there.